Abstract
Objective: To investigate the prevalence, pattern and risk predictors for dyslipidemia among Chinese women with polycystic ovary syndrome (PCOS).
Study Design and Methods: A total of 1,000 women diagnosed as PCOS by modified Rotterdam criteria were enrolled in 27 hospitals across China in a randomized controlled trial. Anthropometric, metabolic parameters, sex hormone, and lipid levels were measured at the baseline visit. Dyslipidemia was defined according to total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) level. Independent t-test and logistic regression were used to identify predictors for dyslipidemia. Area under the receiver operating characteristic curve (AUC) was calculated.
Results: A total of 41.3% of the women had dyslipidemia, and the prevalence of abnormal TC, LDL-C, HDL-C, and TG were 8.6, 9.1, 26.9, and 17.5%, respectively. Logistic regression found that age, waist circumference, insulin, follicle-stimulating hormone, and sex hormone-binding globulin were independent predictors for dyslipidemia. When combining these predictors, the AUC was 0.744. The cut-off points were age >28.5 years, waist circumference >86.5 cm, insulin >96.0 pmol/L, follicle-stimulating hormone <5.6 mIU/mL, and sex hormone-binding hormone <31.0 nmol/L, respectively.
Conclusion: Dyslipidemia was common in Chinese women with PCOS, and low HDL-C level was the predominant lipid abnormality. Age, waist circumference, follicle-stimulating hormone, insulin and sex hormone-binding globulin were predictive for dyslipidemia among Chinese women with PCOS.
Introduction
Cardiovascular disease (CVD) is the leading cause of death globally (). Dyslipidemia is a major risk factor for development and progression of CVD. Previous studies have reported that high levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) and low level of high-density lipoprotein cholesterol (HDL-C) are associated with increased risk of CVD (–).
Polycystic ovary syndrome (PCOS) is one of the most common reproductive disorders in childbearing-aged women, manifested with menstrual disorder, hyperandrogenism, infertility, and polycystic ovary morphology (). PCOS presented a cluster of metabolic abnormalities that are linked with an increased risk of CVD (). Dyslipidemia is also common in PCOS. In a meta-analysis, Wild et al. reported that TG levels were 26 mg/dL higher, LDL-C were 12 mg/dL higher, non-HDL-C concentrations were 19 mg/dL higher, and HDL-C concentrations were 6 mg/dL lower in women with PCOS than those of controls (). The prevalence of dyslipidemia is also higher in women with PCOS compared to control women (), and up to 50–70% in some studies (, ). Furthermore, more research found that dyslipidemia is related to female reproductive health. Serum lipid levels were associated with clinical pregnancy, live birth and miscarriage in women undergoing assisted reproduction (). Previous study showed that abnormal TC, TG, LDL-C, and HDL-C levels were associated with increased number of oocytes retrieved in women with PCOS undergoing unstimulated natural cycles (). High serum TC was also a risk factor for reproductive outcomes of PCOS patients undergoing assisted reproduction (). Therefore, screening for dyslipidemia may not only help to evaluate the cardiometabolic health, but also useful to predict reproductive outcomes after fertility treatment for women with PCOS.
To date, there were few studies focused on the dyslipidemia of Chinese women with PCOS. Therefore, we aimed to determine the prevalence, pattern, and predictors for dyslipidemia in a cohort of Chinese women with PCOS from a well-designed randomized controlled trial.
Methods
Design
This is a baseline cross-sectional analysis of a randomized controlled trial in China, which was published elsewhere (). Patients were recruited from July 2012 to November 2014. Total 1,000 women were included in 27 tertiary or secondary hospitals across China mainland. This trial was registered on ClinicalTrials.gov (NCT01573858) and chictr.org.cn (ChiCTR-TRC-12002081). The trial protocol was approved in ethical committees in all local sites. All patients signed an informed consent. Details of the trial can be found in the main article of this trial ().
Patients
In this trial, all participants were diagnosed as PCOS by the modified Rotterdam criteria (), which is also Chinese version of PCOS diagnosis criteria (). Participants were required to have oligomenorrhea (defined as a menstrual interval >35 days or <8 menses in the past year) or amenorrhea (define as a menstrual interval >90 days), together with hyperandrogenism [clinical hyperandrogenism: modified Ferriman-Gallwey hirsutism score ≥ 5 (), biochemical hyperandrogenism: serum total testosterone >1.67 nmol/L], polycystic ovaries morphology in ultrasound (≥ 12 antral follicles 2–9 mm or ovarian volume ≥ 10 cm3) or both. Patients with metabolic diseases including type one or type two diabetes, any liver and renal diseases were excluded.
Measurements
At the baseline visit, all participants underwent a comprehensive physical evaluation in a standard method by a research assistant. Height, weight, waist circumference (WC), hip circumference (HC), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured and body mass index (BMI) was calculated by height and weight by the following formulas: BMI = weight(kg)/height(m)2.
Blood samples were collected at day 3 in the menstrual cycle for each participant at baseline visit. All blood samples were shipped back to the core laboratory at Heilongjiang University of Chinese Medicine for measurement. Metabolic and endocrinologic parameter including glucose, insulin, progesterone, testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), total testosterone, and sex hormone-binding globulin (SHBG) were measured. Homeostatic model assessment-insulin resistance (HOMA-IR) was calculated by glucose and insulin by the following formulas: HOMA-IR = [insulin(mIU/L) × glucose(mmol/L)]/22.5. Lipids panel included HDL-C, LDL-C, TG, TC, apolipoprotein A1 (APOA1), apolipoprotein B (APOB), and lipoprotein (LP).
Definition of Dyslipidemia
Dyslipidemia was defined in accordance with the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults as follows: TC levels ≥ 6.22 mmol/L, TG levels ≥ 2.26 mmol/L, LDL-C levels ≥ 4.14 mmol/L, and HDL-C levels ≤ 1.04 mmol/L ().
Laboratory Assessment
HDL-C and LDL-C were measured by direct-method assays, and TG and TC were measured by the N-(3-sulfopropyl)-3-methoxy-5-methylaniline method (Wako Diagnostics). Serum APOA1 and APOB levels were determined by the polyethylene glycol-enhanced immunoturbidimetric assay (Maker). Glucose was measured with a hexokinase assay (Maker), insulin, total testosterone, E2, progesterone, FSH, and LH were analyzed with an electrochemiluminescence immunoassay (Roche Diagnostics). SHBG was measured by chemiluminescence immunoassay (Siemens).
Statistical Analysis
All data were analyzed using SPSS Statistics 25.0 version (IBM SPSS, Inc., Chicago, IL, USA). Data were presented as mean ± standard deviation or number with frequency. Independent t-test and chi-square test were used to compare between groups. Logistic regression analysis was performed to explore the association between potential predictors for dyslipidemia. The receiver operating characteristic (ROC) curve and area under the curve (AUC) was used to evaluate the predictive ability for dyslipidemia. The cut-off point of a predictor was defined as the value with highest sum of sensitivity and specificity. P < 0.05 was considered statistically significant.
Results
A total of 1,000 Chinese women with PCOS were included. The women had a mean age of 27.9 ± 3.3 years, an average BMI of 24.2 ± 4.3 kg/m2. The mean values of TC, LDL-C, HDL-C, and TG were 4.7 ± 1.1, 3.0 ± 0.9, 1.3 ± 0.4, and 1.6 ± 0.9 mmol/L, respectively. A total of 413 (41.3%) of these women were diagnosed with dyslipidemia. The prevalence of abnormal TC, LDL-C, HDL-C, and TG were 8.6, 9.1, 26.9, and 17.5%, respectively. 24.7% of women had only one type of lipid abnormality and 16.6% of women had more than one type of lipid abnormality (Figure 1).
Figure 1
Table 1 demonstrated the baseline characteristics of all 1,000 women and women with and without dyslipidemia. PCOS women with dyslipidemia had increased age, BMI, WC, HC, SBP, DBP, duration of infertility, insulin, HOMA-IR, lower LH, FSH, LH/FSH ratio and SHBG compared to women without dyslipidemia.
Table 1
| Characteristics | Total PCOS women (n = 1,000) | With dyslipidemia (n = 413) | Without dyslipidemia (n = 587) | Pvalue* |
|---|---|---|---|---|
| Age (year) | 27.9 ± 3.3 | 28.4 ± 3.5 | 27.5 ± 3.1 | <0.001 |
| BMI (kg/m2) | 24.2 ± 4.3 | 25.7 ± 4.1 | 23.1 ± 4.1 | <0.001 |
| HC (cm) | 98.5 ± 8.6 | 100.8 ± 8.6 | 96.5 ± 8.1 | <0.001 |
| WC (cm) | 85.4 ± 11.5 | 89.4 ± 11.1 | 82.4 ± 10.8 | <0.001 |
| SBP (mmHg) | 112.3 ± 9.4 | 113.6 ± 9.0 | 111.3 ± 9.6 | <0.001 |
| DBP (mmHg) | 74.9 ± 7.9 | 75.4 ± 7.9 | 74.4 ± 7.8 | 0.049 |
| Duration of infertility (month) | 24.0 ± 17.8 | 25.8 ± 18.8 | 22.4 ± 16.5 | 0.004 |
| Current smoking | 12 (1.2%) | 8 (1.9%) | 4 (0.7%) | 0.098 |
| Current drinking | 91 (9.1%) | 42 (10.2%) | 48 (8.2%) | 0.423 |
| Insulin (pmol/L) | 98.1 ± 108.5 | 124.8 ± 135.4 | 76.4 ± 70.9 | <0.001 |
| Glucose (mmol/L) | 5.0 ± 1.0 | 5.1 ± 1.2 | 5.0 ± 0.8 | 0.051 |
| HOMA-IR | 3.3 ± 3.6 | 4.2 ± 4.1 | 2.5 ± 2.8 | <0.001 |
| Progesterone (nmol/L) | 2.8 ± 7.9 | 2.7 ± 10.0 | 2.8 ± 5.5 | 0.826 |
| Testosterone (nmol/L) | 1.7 ± 0.6 | 1.7 ± 0.7 | 1.7 ± 0.6 | 0.585 |
| LH (mIU/mL) | 10.6 ± 6.4 | 9.6 ± 5.5 | 11.4 ± 6.9 | <0.001 |
| FSH (mIU/mL) | 6.1 ± 1.7 | 5.9 ± 1.6 | 6.3 ± 1.8 | <0.001 |
| LH/FSH ratio | 1.8 ± 1.1 | 1.7 ± 0.9 | 1.9 ± 1.3 | 0.003 |
| E2 (pmol/L) | 269.6 ± 317.5 | 256.6 ± 325.0 | 278.8 ± 310.8 | 0.286 |
| SHBG (nmol/L) | 42.6 ± 30.7 | 32.9 ± 24.7 | 49.9 ± 32.6 | <0.001 |
| Lipid profile | ||||
| TC (mmol/L) | 4.7 ± 1.1 | 4.9 ± 1.4 | 4.6 ± 0.7 | <0.001 |
| LDL-C (mmol/L) | 3.0 ± 0.9 | 3.2 ± 1.1 | 2.8 ± 0.6 | <0.001 |
| HDL-C (mmol/L) | 1.3 ± 0.4 | 1.1 ± 0.4 | 1.4 ± 0.3 | <0.001 |
| TG (mmol/L) | 1.6 ± 0.9 | 2.1 ± 1.1 | 1.1 ± 0.4 | <0.001 |
| ApoA1 (g/L) | 1.5 ± 0.3 | 1.4 ± 0.3 | 1.6 ± 0.3 | <0.001 |
| ApoB (g/L) | 0.9 ± 0.3 | 1.0 ± 0.3 | 0.8 ± 0.2 | <0.001 |
| LP (mg/L) | 130.1 ± 102.6 | 128.2 ± 95.8 | 131.8 ± 107.6 | 0.589 |
Characteristics of all women and women with and without dyslipidemia.
P values for comparisons between with dyslipidemia and without dyslipidemia.
Data are presented as mean ± SD or number (frequency).
BMI, body mass index; HC, hip circumference; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment for insulin resistance; LH, luteinizing hormone; FSH, follicle-stimulating hormone; E2, estradiol; SHBG, sex hormone-binding globulin; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; LP, lipoprotein.
Univariate logistic regression analysis showed that age, BMI, WC, HC, SBP, DBP, duration of infertility, glucose, insulin, and HOMA-IR were significantly associated with higher chance of dyslipidemia, while LH, FSH, and SHBG were significantly associated with lower chance of dyslipidemia (Table 2). By backward selection, multivariate logistic regression analysis showed that age (OR = 1.08, 95% CI: 1.03–1.13, P < 0.001), WC (OR = 1.03, 95% CI: 1.02–1.05, P < 0.001), insulin (OR = 1.004, 95% CI: 1.002–1.007, P < 0.001), FSH (OR = 0.90, 95% CI: 0.83–0.99, P = 0.022) and SHBG (OR = 0.98, 95% CI: 0.98–0.99, P < 0.001) were independent predictors for dyslipidemia in Chinese women with PCOS (Table 3).
Table 2
| Odds ratio | 95% confidence interval | Pvalue | |
|---|---|---|---|
| Age (year) | 1.09 | 1.04–1.13 | <0.001 |
| BMI (kg/m2) | 1.17 | 1.13–1.21 | <0.001 |
| HC (cm) | 1.06 | 1.05–1.08 | <0.001 |
| WC (cm) | 1.06 | 1.05–1.07 | <0.001 |
| SBP (mmHg) | 1.03 | 1.01–1.04 | <0.001 |
| DBP (mmHg) | 1.02 | 1.00–1.03 | 0.049 |
| Duration of infertility (month) | 1.01 | 1.00–1.02 | 0.004 |
| Current smoking | 2.67 | 0.80–8.93 | 0.112 |
| Current drinking | 1.20 | 0.77–1.85 | 0.423 |
| Insulin (pmol/L) | 1.008 | 1.006–1.011 | <0.001 |
| Glucose (mmol/L) | 1.15 | 1.01–1.31 | 0.042 |
| HOMA-IR | 1.21 | 1.14–1.28 | <0.001 |
| Progesterone (nmol/L) | 1.00 | 0.98–1.02 | 0.826 |
| Testosterone (nmol/L) | 1.06 | 0.87–1.29 | 0.584 |
| LH (mIU/mL) | 0.95 | 0.93–0.97 | <0.001 |
| FSH (mIU/mL) | 0.87 | 0.80–0.94 | <0.001 |
| E2 (pmol/L) | 1.00 | 1.00–1.00 | 0.292 |
| SHBG (nmol/L) | 0.98 | 0.97–0.98 | <0.001 |
Univariate logistic analysis of the predictors for dyslipidemia.
BMI, body mass index; HC, hip circumference; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment for insulin resistance; LH, luteinizing hormone; FSH, follicle-stimulating hormone; E2, estradiol; SHBG, sex hormone-binding globulin.
Table 3
| Odds ratio | 95% confidence interval | Pvalue | |
|---|---|---|---|
| Age (year) | 1.08 | 1.03–1.13 | <0.001 |
| WC (cm) | 1.03 | 1.02–1.05 | <0.001 |
| Insulin (pmol/L) | 1.004 | 1.002–1.007 | <0.001 |
| FSH (mIU/mL) | 0.90 | 0.83–0.99 | 0.022 |
| SHBG (nmol/L) | 0.98 | 0.98–0.99 | <0.001 |
Multivariate logistic analysis of the predictors for dyslipidemia by backward selection.
WC, waist circumference; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin.
ROC curves were used to predict dyslipidemia (Figure 2). AUC of age, WC, insulin, FSH, and SHBG for dyslipidemia were 0.571, 0.683, 0.698, 0.574, and 0.698, respectively (Table 4). The cut-off points of age, WC, insulin, FSH, and SHBG were >28.5 years, >86.5 cm, >96.0 pmol/L, <5.6 mIU/mL, and <31.0 nmol/L, respectively. Sensitivity and specificity were listed in Table 4. When combined all of the above predictors, the AUC was up to 0.744 (95% CI: 0.713–0.775) for dyslipidemia.
Figure 2
Table 4
| Cut-off value | Sensitivity | Specificity | AUC | 95% confidence interval | |
|---|---|---|---|---|---|
| Age (year) | >28.5 | 47.2% | 64.0% | 0.571 | 0.534–0.608 |
| WC (cm) | >86.5 | 58.1% | 70.5% | 0.683 | 0.650–0.717 |
| Insulin (pmol/L) | >96.0 | 50.7% | 79.6% | 0.698 | 0.663–0.731 |
| FSH (mIU/mL) | <5.6 | 69.1% | 45.3% | 0.574 | 0.537–0.611 |
| SHBG (nmol/L) | <31.0 | 67.8% | 61.7% | 0.698 | 0.663–0.730 |
AUC, sensitivity, specificity for cut-off points of each predictor for dyslipidemia.
AUC, The area under ROC curve; WC, waist circumference; FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin.
Discussion
This study assessed the prevalence, pattern and predictors for dyslipidemia in Chinese women with PCOS. We found that prevalence of dyslipidemia is high in Chinese women with PCOS, and the most common type is low HDL-C. Age, WC, insulin, FSH, and SHBG were significant independent predictors for dyslipidemia. The overall predictability is good.
Several studies had reported the pattern and predictors for dyslipidemia in women with PCOS. One study reported that the prevalence of dyslipidemia was 76.1% and low HDL-C (57.6%) is the predominant lipid abnormality in Brazilian women with PCOS, and BMI had a significant impact on this abnormality (). Another study found that the 72.4% of non-Hispanic women with PCOS had dyslipidemia and elevation in LDL-C was most frequent, and the significant predictors were age, insulin, and testosterone (). In our study, the overall prevalence of dyslipidemia was 41.3% and low HDL-C was most common (26.9%). The low prevalence of dyslipidemia in Chinese women with PCOS might be explained be by the relatively lower BMI (, ).
Dyslipidemia is closely related to the occurrence and progress of CVD due to its role on atherosclerosis (). TC, LDL-C and TG are atherogenic and represent risk factors of CVD, and LDL-C remains the primary target in lipid lowering therapy (). HDL-C exerts athero-protective effects and prevent the CVD due to its role its role in reverse cholesterol transport () and favorable function on inflammation, oxidation, angiogenesis, and glucose homeostasis (). Anti-inflammatory and antioxidant role of HDL-C is increasingly considered to be beneficial for reproductive health (). Previous studies reported that HDL-C in follicular fluid has considerable antioxidative properties and is beneficial for the development of human oocytes and embryos (, ). Unfavorable serum lipid levels were also associated with worse reproductive outcomes in women undergoing assisted reproduction (). Since low HDL-C was the most frequent type of dyslipidemia, strategies to improve HDL-C level might bring additional benefits for women with PCOS.
Some features have been reported to be associated with dyslipidemia. Aging is related to disorders of lipid metabolism through multiple pathways (). WC is one of the most practical measurements for abdominal obesity, which contribute to the dyslipidemia and other metabolic traits of PCOS (). Insulin resistance was associated with serum lipid level in women with PCOS (). Our results confirmed that age, WC, and insulin were predictors for dyslipidemia in Chinese women with PCOS.
Some studies have evaluated the relation between FSH and lipid levels in postmenopausal women. One study found FSH was positively and linearly associated with TC and LDL-C (). FSH may interact with its receptors in hepatocytes and reduce LDL receptor levels, which subsequently attenuates the endocytosis of LDL-C, resulting in an elevated circulating LDL-C level in postmenopausal women (). On the contrary, we found that higher FSH level was associated with lower chance of dyslipidemia in women with PCOS. Under the regulation of FSH and its receptor, the oocyte relies on serum lipids from the maternal circulation to provide cholesteryl esters for granulosa cell steroidogenesis. We hypothesize that higher FSH level may stimulate the estrogen synthesis pathway, which lead to less lipid accumulation in circulation due to the increased synthesis of estrogen.
Our study also found protective role of SHBG on dyslipidemia in women with PCOS. Previous studies found that increased lipoprotein lipase activity was associated with better lipid metabolism, and a positive correlation between SHBG and lipoprotein lipase activity was observed (). Since both lipid metabolism and SHBG production occur in the liver, the relationship between lipid and SHBG may reflect the changes of liver metabolism. SHBG may affect lipid metabolism by regulating insulin resistance. SHBG could affect glucose transporters and PI3K/AKT pathway (, ). Recent studies have found that lower SHBG is an independent risk factor for type two diabetes, and there is strong genetic evidence that SHBG is associated with the etiology of type two diabetes (, ). A previous study assessed SHBG levels in women with PCOS, and found that low SHBG levels were associated with gestational diabetes mellitus (37). Genetic studies also found that the causal relationship between SHBG, insulin resistance and diabetes is weak, indicating that the correlation was partially confounded rather than directly endowed by circulating SHBG (38).
Since the prevalence of dyslipidemia is rather high in women with PCOS, evaluation for lipid level is recommended. The current study showed that age, WC, insulin, FSH, and SHBG were predictors for dyslipidemia in women with PCOS. Age >28.5 years old, WC >86.5 cm, insulin >96.0 IU/L, FSH >5.6 mIU/mL, and SHBG <31.0 nmol/L were suggestive for lipid evaluation in Chinese women with PCOS.
Hyperandrogenism is regarded as a key element of the pathophysiology of PCOS, which is responsible for many clinical features of PCOS and reflect the severity of the syndrome. However, we didn't find that testosterone was a significant predictor for dyslipidemia. One study also found no correlation between testosterone and dyslipidemia in women with PCOS (39). We hypothesized that dyslipidemia may contribute more than traditionally thought in the development of PCOS.
Follicular microenvironment is the location for folliculogenesis, oocyte meiosis and steroidogenesis. Serum lipid metabolites could be transferred from circulation to follicular fluid, and directly contact with oocyte. Lipidomics analysis identified 32 differential lipids in the follicular fluid of PCOS women compared to control women (40). Previous study showed that high levels of serum lipid metabolic parameters were associated with increased number of oocytes retrieved in women with PCOS undergoing unstimulated natural cycles (). We hypothesized that dyslipidemia might be an underlying cause of PCOS. The association between lipid metabolites in serum and follicular fluid, and the association between them and folliculogenesis, oocyte quality in women with PCOS still need more research in the future.
There are several strengths of this study. First, the women were recruited from different sites across different geographical regions in China mainland, which increased the generalizability of the cohort. Second, common clinical data were collected in a standardized method, blood samples were stored in a standard method and measured in a core laboratory. However, data of some participants were missing, which might decrease the statistical power. In addition, some characteristics of the subjects were lacking, such as physical activity, which might affect lipid metabolism. Additionally, the women didn't have a long-term follow-up and therefore we cannot evaluate the real cardiovascular health.
In conclusion, dyslipidemia was common in Chinese women with PCOS, and low HDL-C level was the predominant lipid abnormality. Older age, higher WC, higher insulin, lower FSH, and lower SHBG were predictive for dyslipidemia among Chinese women with PCOS.
Funding
This was funded by National Public Welfare Projects for Chinese Medicine (201107005 and 200807002), the National Key Discipline of Chinese Medicine in Gynecology during the year of 2009–2016 (JC200804), the Intervention for Polycystic Ovary Syndrome Based on Traditional Chinese Medicine Theory—Tian Gui Disorder (2011TD006), and the National Clinical Trial Base in Chinese Medicine Special Projects (JDZX2012036 and 2015B009) during the year of 2009–2016 for the First Affiliated Hospital, Heilongjiang University of Chinese Medicine, as well as the Heilongjiang Province Longjiang Schola Program to X-KW.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.
Ethics statement
The studies involving human participants were reviewed and approved by First Affiliated Hospital, Heilongjiang University of Chinese Medicine. The patients/participants provided their written informed consent to participate in this study.
Author contributions
X-KW designed the study and critically revised the manuscript. W-YC and XL performed data analysis, drafted manuscript, interpreted the results, and revised the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
RothGAMensahGAJohnsonCOAddoloratoGAmmiratiEBaddourLMet al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. (2020) 76:2982–3021. 10.1016/j.jacc.2020.11.010
2.
PetersSAESinghatehYMackayDHuxleyRRWoodwardM. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis. Atherosclerosis. (2016) 248:123–31. 10.1016/j.atherosclerosis.2016.03.016
3.
DomanskiMJTianXWuCOReisJPDeyAKGuYet al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. (2020) 76:1507–16. 10.1016/j.jacc.2020.07.059
4.
SarwarNDaneshJEiriksdottirGSigurdssonGWarehamNBinghamSet al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. (2007) 115:450–8. 10.1161/CIRCULATIONAHA.106.637793
5.
NavabMReddySTVan LentenBJFogelmanAM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. (2011) 8:222–32. 10.1038/nrcardio.2010.222
6.
RotterdamESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. (2004) 19:41–7. 10.1093/humrep/deh098
7.
WekkerVvan DammenLKoningAHeidaKYPainterRCLimpensJet al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. (2020) 26:942–60. 10.1093/humupd/dmaa029
8.
WildRARizzoMCliftonSCarminaE. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. (2011) 95:1073–9.e1–11. 10.1016/j.fertnstert.2010.12.027
9.
KrentowskaAKowalskaI. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab Res Rev. (2021). 10.1002/dmrr.3464. [Epub ahead of print].
10.
LiHLiLGuJLiYChenXYangD. Should all women with polycystic ovary syndrome be screened for metabolic parameters?: a hospital-based observational study. PLoS ONE. (2016) 11:e0167036. 10.1371/journal.pone.0167036
11.
LegroRSKunselmanARDunaifA. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. (2001) 111:607–13. 10.1016/S0002-934300948-2
12.
CaiWYLuoXChenELvHFuKWuXKet al. serum lipid levels and treatment outcomes in women undergoing assisted reproduction: a retrospective cohort study. Front Endocrinol. (2021) 12:633766. 10.3389/fendo.2021.633766
13.
LiuTLiuDSongXQuJZhengXLiJet al. Lipid metabolism was associated with oocyte maturation in women with polycystic ovarian syndrome undergoing unstimulated natural cycle. Front Cell Dev Biol. (2021) 9:719173. 10.3389/fcell.2021.719173
14.
GaoLLiMWangYZengZXieYLiuGet al. Overweight and high serum total cholesterol were risk factors for the outcome of IVF/ICSI cycles in PCOS patients and a PCOS-specific predictive model of live birth rate was established. J Endocrinol Invest. (2020) 43:1221–8. 10.1007/s40618-020-01209-5
15.
WuXKStener-VictorinEKuangHYMaHLGaoJSXieLZet al. Effect of acupuncture and clomiphene in chinese women with polycystic ovary syndrome: a randomized clinical trial. JAMA. (2017) 317:2502–14. 10.1001/jama.2017.7217
16.
ChenZTianQQiaoJHuangHLiuJYangDet al. Diagnosis and treatment of polycystic ovary syndrome: standard and guideline of ministry of health of People's Republic of China. Zhonghua Fu Chan Ke Za Zhi. (2018) 53:2–6. 10.3760/cma.j.issn.0529-567X.2018.01.002
17.
LiRQiaoJYangDLiSLuSWuXet al. Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system. Eur J Obstet Gynecol Reprod Biol. (2012) 163:165–9. 10.1016/j.ejogrb.2012.03.023
18.
Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. [Chinese guidelines on prevention and treatment of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. (2007) 35:390–419. 10.3760/j.issn:0253-3758.2007.05.003
19.
RochaMPMarcondesJAMBarcellosCRGHayashidaSAYCuriDDGda FonsecaÂMet al. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Gynecol Endocrinol. (2011) 27:814–9. 10.3109/09513590.2010.508852
20.
LegroRSBrzyskiRGDiamondMPCoutifarisCSchlaffWDCassonPet al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. (2014) 371:119–29. 10.1056/NEJMoa1313517
21.
TabasIWilliamsKJBorénJ. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. (2007) 116:1832–44. 10.1161/CIRCULATIONAHA.106.676890
22.
StoneNJRobinsonJGLichtensteinAHBairey MerzCNBlumCBEckelRHet al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. (2014) 63(25 Pt B):2889–934. 10.1016/j.jacc.2013.11.002
23.
FieldingCJFieldingPE. Molecular physiology of reverse cholesterol transport. J Lipid Res. (1995) 36:211–28. 10.1016/S0022-227539898-9
24.
NichollsSJNelsonAJ. HDL and cardiovascular disease. Pathology. (2019) 51:142–7. 10.1016/j.pathol.2018.10.017
25.
FujimotoVYKaneJPIshidaBYBloomMSBrowneRW. High-density lipoprotein metabolism and the human embryo. Hum Reprod Update. (2010) 16:20–38. 10.1093/humupd/dmp029
26.
KimKBloomMSBrowneRWBellEMYucelRMFujimotoVY. Associations between follicular fluid high density lipoprotein particle components and embryo quality among in vitro fertilization patients. J Assist Reprod Genet. (2017) 34:1–10. 10.1007/s10815-016-0826-x
27.
LiuHHLiJJ. Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev. (2015) 19:43–52. 10.1016/j.arr.2014.12.001
28.
Couto AlvesAValcarcelBMäkinenVPMorin-PapunenLSebertSKangasAJet al. Metabolic profiling of polycystic ovary syndrome reveals interactions with abdominal obesity. Int J Obes. (2017) 41:1331–40. 10.1038/ijo.2017.126
29.
KheirollahiATeimouriMKarimiMVatannejadAMoradiNBorumandniaNet al. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women. Lipids Health Dis. (2020) 19:235. 10.1186/s12944-020-01410-8
30.
ServienteCTuomainenTPVirtanenJWitkowskiSNiskanenLBertone-JohnsonE. Follicle-stimulating hormone is associated with lipids in postmenopausal women. Menopause. (2019) 26:540–5. 10.1097/GME.0000000000001273
31.
SongYWangESXingLLShiSQuFZhangDet al. Follicle-stimulating hormone induces postmenopausal dyslipidemia through inhibiting hepatic cholesterol metabolism. J Clin Endocrinol Metab. (2016) 101:254–63. 10.1210/jc.2015-2724
32.
DesmeulesACouillardCTchernofABergeronJRankinenTLeonASet al. Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: The HERITAGE family study. Atherosclerosis. (2003) 171:343–50. 10.1016/j.atherosclerosis.2003.08.018
33.
FengCJinZSunLWangXChiXZhangXet al. Endogenous SHBG levels correlate with that of glucose transporters in insulin resistance model cells. Mol Biol Rep. (2019) 46:4953–65. 10.1007/s11033-019-04946-w
34.
FengCJinZChiXZhangBWangXSunLet al. SHBG expression is correlated with PI3K/AKT pathway activity in a cellular model of human insulin resistance. Gynecol Endocrinol. (2018) 34:567–73. 10.1080/09513590.2017.1411474
35.
DingELSongYMansonJEHunterDJLeeCCRifaiNet al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. (2009) 361:1152–63. 10.1056/NEJMoa0804381
36.
PerryJRWeedonMNLangenbergCJacksonAULyssenkoVSparsoTet al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet. (2010) 19:535–44. 10.1093/hmg/ddp522
37.
Veltman-VerhulstSMvan HaeftenTWEijkemansMJde ValkHWFauserBCGoverdeAJ. Sex hormone-binding globulin concentrations before conception as a predictor for gestational diabetes in women with polycystic ovary syndrome. Hum Reprod. (2010) 25:3123–8. 10.1093/humrep/deq272
38.
WangQKangasAJSoininenPTiainenMTynkkynenTPuukkaKet al. Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: observational and causal effect estimates. Int J Epidemiol. (2015) 44:623–37. 10.1093/ije/dyv093
39.
OzegowskaKKormanMSzmytAPawelczykL. Heterogeneity of endocrinologic and metabolic parameters in reproductive age Polycystic Ovary Syndrome (PCOS) women concerning the severity of hyperandrogenemia-a new insight on syndrome pathogenesis. Int J Environ Res Public Health. (2020) 17:9291. 10.3390/ijerph17249291
40.
BanYRanHChenYMaL. Lipidomics analysis of human follicular fluid form normal-weight patients with polycystic ovary syndrome: a pilot study. J Ovarian Res. (2021) 14:135. 10.1186/s13048-021-00885-y
Summary
Keywords
polycystic ovary syndrome, dyslipidemia, prevalence, predictor, HDL
Citation
Luo X, Cai W-Y and Wu X-K (2021) Prevalence, Pattern and Predictors for Dyslipidemia of Chinese Women With Polycystic Ovary Syndrome. Front. Cardiovasc. Med. 8:790454. doi: 10.3389/fcvm.2021.790454
Received
06 October 2021
Accepted
25 November 2021
Published
15 December 2021
Volume
8 - 2021
Edited by
Nathalie Pamir, Oregon Health and Science University, United States
Reviewed by
Hongxue Shi, Columbia University, United States; Woosuk Steve Hur, University of North Carolina at Chapel Hill, United States
Updates
Copyright
© 2021 Luo, Cai and Wu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiao-Ke Wu xiaokewu2002@vip.sina.com; orcid.org/0000-0002-8339-9242
†These authors share first authorship
This article was submitted to Lipids in Cardiovascular Disease, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.